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We report on the fabrication and characterisation of graphene field-effect transistor
(GFET) biosensors for the detection of Clusterin, a prominent protein biomarker of
Alzheimer’s disease (AD). The GFET sensors were fabricated on Si/SiO2 substrate using
photolithographic patterning and metal lift-off techniques with evaporated chromium
and sputtered gold contacts. Raman Spectroscopy was performed on the devices
to determine the quality of the graphene. The GFETs were annealed to improve their
performance before the channels were functionalized by immobilising the graphene
surface with linker molecules and anti-Clusterin antibodies. Concentration of linker
molecules was also independently verified by absorption spectroscopy using the highly
collimated micro-beam light of Diamond B23 beamline. The detection was achieved
through the binding reaction between the antibody and varying concentrations of
Clusterin antigen from 1 to 100 pg/mL, as well as specificity tests using human
chorionic gonadotropin (hCG), a glycoprotein risk biomarker of certain cancers. The
GFETs were characterized using direct current (DC) 4-probe electrical resistance (4-
PER) measurements, which demonstrated a limit of detection of the biosensors
to be ∼ 300 fg/mL (4 fM). Comparison with back-gated Dirac voltage shifts with
varying concentration of Clusterin show 4-PER measurements to be more accurate, at
present, and point to a requirement for further optimisation of the fabrication processes
for our next generation of GFET sensors. Thus, we have successfully fabricated a
promising set of GFET biosensors for the detection of Clusterin protein biomarker.
The developed GFET biosensors are entirely generic and also have the potential to be
applied to a variety of other disease detection applications such as Parkinson’s, cancer,
and cardiovascular.
Keywords: graphene, field-effect transistors, biosensor, Clusterin protein, Alzheimer’s disease, SRCD
absorbance spectroscopy, DNA and molecular diagnostics, cancer and cardiovascular disease detection
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INTRODUCTION
Graphene, a single atomic plane of carbon, was considered to be
thermodynamically unstable until 17 years ago. Novoselov et al.
(2004) experimentally demonstrated that graphene can exist in
the free state at room temperature, and that it is stable as a single
layer of graphene making it a zero bandgap semiconductor. The
monolayer of sp2 bonded carbon atoms is tightly packed into
a two-dimensional (2D) sheet arranged in a honeycomb lattice.
Graphene has the potential to advance many technological areas
because of its outstanding material properties such as its high
carrier mobility (Novoselov et al., 2004, 2005b; Bolotin et al.,
2008; Morozov et al., 2008), current carrying capacity (Castro
Neto et al., 2009), thermal conductivity (Balandin et al., 2008),
optical properties (Blake et al., 2008), and mechanical stability
(Booth et al., 2008). It is being researched for various applications
such as high-speed electronics (Lin et al., 2010; Awan et al.,
2016), optoelectronics (Bao and Loh, 2012), solar cells (Wang
et al., 2008), energy storage (Wang et al., 2009), electromechanical
resonators (Bunch et al., 2007), composites (Stankovich et al.,
2006), and biosensors (Justino et al., 2017; Haslam et al., 2018;
Vu and Chen, 2019).
Graphene is ideally suited to applications in biosensing due
to its large surface-to-volume ratio, biocompatibility, chemical
stability, ease of surface functionalisation, field effect-based
ambipolar transport of electrons and holes, and excellent
electrical conductivity (Geim and Novoselov, 2010), which are
highly beneficial for good sensor performance such as increased
sensitivity and a low limit of detection (LOD). Among the
many graphene-based biosensor applications, graphene field-
effect transistors (GFETs) are widely regarded as a promising
platform for biosensing (Haslam et al., 2018; Bunch et al., 2020).
The graphene channel in GFETs is typically exposed to the
charged biological environment and is able to detect the presence
of biomolecules electrically, based on resistance/conductance
change caused by the binding of receptor molecules with a
given antigen biomarker (enzymes, proteins, peptides, DNA,
etc.). Dong et al. (2010), Okamoto et al. (2012), and Vu and
Chen (2019). GFET is a powerful biosensing platform due to its
relative simplicity in sensor preparation but also high signal-to-
noise ratio, low-cost, portability, and relative ease of integration
with a range of existing electronic systems. GFETs consume less
energy, can be scaled down and can operate at higher frequencies
making them a flexible platform for biosensing (Novoselov et al.,
2004, 2005a; Awan et al., 2016). Such GFET biosensors are being
researched extensively for early diagnosis of not only Alzheimer’s
disease (AD) but also for a variety of other diseases such as
Parkinson’s, cancer and cardiovascular.
Here, we report on the detection of Clusterin, a prominent
protein biomarker of AD using both electrical and B23
absorption spectroscopy approaches. AD is a sub-type
of dementia responsible for around 60–70% of cases in
neurodegenerative diseases. There are approximately 54 million
people currently living with dementia worldwide and this
number is expected to rise to 130 million by 2050, and an
estimated 9.9 million people will develop the disease every year
(Alzheimer’s Society, 2020). AD is an incurable and long-term
neurodegenerative disease that progressively worsens over time.
It is believed to be caused by abnormal build-up of proteins in
and around the brain. Tests have revealed deposits of protein
around the extracellular and intracellular compartments of a
post-mortem AD brain, the intracellular deposits were made
up of filaments of hyperphosphorylated tau protein (Iqbal
et al., 2005). Evidence has shown that neurofibrillary tangles
(NFTs), consisting of hyperphosphorylated tau, are present
within the neurons of AD patients; NFTs disrupt the normal
communication between neurons (Selkoe, 1991). While the
extracellular deposits also known as amyloid plagues are most
commonly found in the neocortex (responsible for sensory
perception, reasoning, conscious thoughts, generation of motor
commands, and language in humans). The neocortex consists
of 4-kDa polypeptide known as the β-amyloid (Aβ) (Glenner
and Wong, 1984; Masters et al., 1985). Research has shown
considerable evidence that neurodegeneration that occurs in
AD patients is as a result of the accumulation and aggregation
of Aβ. Aβ plaques are formed within the medial temporal lobe
and also within the cerebral cortex of the brain tissue. This
Aβ formation is attributed to the abnormal metabolism of
β-amyloid precursor protein (APP) (Hardy and Selkoe, 2002).
The Aβ plaques and NFTs develop over a long period of time
(∼20–30 years) and leads to death of nerve cells and loss of
brain tissues. Clusterin (is encoded by the single copy CLU gene
located at the p21 – p12 locus on chromosome 8 in humans), also
known as apolipoprotein-J, is a glycoprotein found in various
tissues and bodily fluids (De Silva et al., 1990), and it functions as
an extracellular chaperone (Satapathy, 2017). Increased levels of
Clusterin have been found in the frontal cortex and hippocampus
of post-mortem AD brain tissue (May et al., 1990; Lidström et al.,
1998). It was demonstrated that CLU is strongly associated to
soluble Aβ in the cerebral spinal fluid (CSF) (Ghiso et al., 1993),
and it can either prevent the aggregation of Aβ or increase its
solubility (Matsubara et al., 1996). It regulates the formation
and toxicity of Aβ fibril, and also aids in transporting Aβ across
the blood–brain barrier. Clusterin has a molecular weight of
75–80 kDa and is comprised of 449 amino acids (Tsuruta et al.,
1990; James et al., 1991), two ∼40 kDa subunits of α and β
connected by five disulphide bond motif (Kirszbaum et al.,
1992). Clusterin plays an important role in the progression of
AD and it has been identified as one of the key biomarkers of
AD (Thambisetty et al., 2010). It was experimentally shown that
Clusterin was elevated by ∼40% above non-demented controls
in the brain of AD patients (May et al., 1990; Oda et al., 1994).
Different Clusterin levels have been reported for AD patients; 67
AD cases were studied with mean age 85.3 ± 3.2 and Clusterin
plasma levels of 158.5± 45.3 µg/mL (Schürmann et al., 2011), 60
AD cases were studied with mean age 83.4 ± 7.3 with Clusterin
plasma levels of 129 ± 29 µg/mL (Schrijvers et al., 2011), also 17
AD cases with mean age 86.0 ± 6.36 and Clusterin plasma levels
of 106.3 ± 23.7 µg/mL (Thambisetty et al., 2012). Currently,
diagnosis of AD can take up to 2 years involving a range of
different tests such as computer tomography (CT), magnetic
resonance imaging (MRI), positron emission tomography (PET),
neurological evaluation, cognitive, and neuropsychological tests
(Mayo Clinic, 2020). Therefore, the need for a fast, low-cost,
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accurate, non-invasive, and portable means of diagnosing AD at
an early stage is of high importance. Here we demonstrate the
sensitivity, repeatability and specificity of the GFET biosensors
for the detection of pure proteins. The next stage of the study will
be to investigate the sensor response using real patient samples
(such as serum, plasma, or blood), stability and storage of the
sensors (Teixeira et al., 2014; Leva-Bueno et al., 2020; Zupančič
et al., 2021). Thus, GFET biosensors offer a unique route towards
the development of vitally needed diagnostic platform for AD.
MATERIALS AND METHODS
Materials
Monolayer graphene was produced by chemical vapour
deposition (CVD) method on a 300 nm Si/SiO2 substrate,
supplied by Graphenea (San Sebastián, Spain) and LG Electronics
Inc. (Gangseo-gu, Seoul, South Korea). The chemicals used for
the GFET fabrication were photoresist, lift-off resist (LoR),
Microposit developer and Microposit remover, purchased from
A-Gas Electronic Materials (Warwickshire, United Kingdom).
Recombinant human Clusterin protein and anti-Clusterin
antibody were purchased from Abcam (Cambridge,
United Kingdom). Linker molecule 1-pyrenebutanoic acid
succinimidyl ester (Pyr-NHS), bovine serum albumin (BSA)
blocking solution and phosphate-buffered saline (PBS) were
purchased from Sigma-Aldrich (Dorset, United Kingdom). All
measurements were performed at room temperature, pH of 7.4
and using 10 µL samples deposited on the GFET sensors.
The quality of graphene was evaluated using an XPLORA
Raman spectroscopy system (HORIBA, Northampton,
United Kingdom). All measurements on the XPLORA system
were performed at a wavelength of 532 nm, with ∼ 4 mW of
incident power and a grating of 1200T. The XPLORA Raman
system was interfaced with an OLYMPUS BX41 microscope
(Shinjuku, Japan).
The electrical characterisation of the GFETs was performed
under ambient conditions using a Keysight B1500A
semiconductor device parameter analyser interfaced to a MPS150
probe station (Cascade Microtech, Thiendorf, Germany). The
4-probe current–voltage measurements (ID–VD and ID–VG)
were acquired as a function of gate voltage (VG) from −100 V to
+100 V with ID–VD curves from −50 to +50 mV with a 100 µA
compliance. The ID–VD output and ID–VG transfer curves were
measured at each functionalisation stage.
All absorption spectroscopy experiments were performed
on Beamline B23 at Diamond Light Source (Oxfordshire,
United Kingdom) over the 180–400 nm wavelength range, using
a wavelength increment of 1 nm, with cell path length of 1 mm
and at room temperature∼ 22◦C (Hussain et al., 2012).
Fabrication of the Graphene FETs
The GFET sensors were fabricated on a p++ Si/SiO2 substrate
through the processes of photolithographic patterning and metal
lift-off techniques with evaporated chromium and sputtered gold
contacts. There are two major stages in the fabrication process,
the first stage involves forming the graphene channel whereas
the second stage involves forming the source, drain, and voltage
electrodes. A representation of the fabrication process is shown
in Figure 1.
The formation of the graphene channels on the Si/SiO2
substrate involves dicing the samples into sizes of 1 cm × 1 cm
chips before spin-coating the samples with LoR at 3000
revolutions-per-minute (rpm) for 30 s. The samples are then pre-
baked in a fan oven at 175◦C for 15 min. Pre-baking the samples
solidify the LoR as it eases in lifting off the photoresist (PR) while
protecting the graphene channels formed. The next step is spin-
coating the samples with a layer of positive PR at 3000 rpm for
30 s and then post-baking on a hotplate at 100◦C for 60 s. The
post-bake step is to solidify the PR and remove any solvents on
the samples. The samples are then positioned in a mask-aligner
under a patterned mask for creating the graphene channels, and
exposed to ultra-violet (UV) radiation for 25 s. The samples are
then rinsed in a chemical developer mixed with di-ionized water
(20 mL developer mixed with 30 mL di-ionized water), until the
graphene channels are visible under a microscope. There is always
residue of PR/PMMA (poly-methyl methacrylate) on the sample
at this stage, which degrades the quality of the graphene, which
can be reduced by post-baking the samples on a hotplate at 180◦C
for 8 min under deep ultraviolet (DUV) light of 254 nm. The
DUV dissociates the bonds between PR/PMMA and graphene
and reduces contact resistance of the sample.
Next, the samples are transferred into a sputtering machine
for Ar plasma etching. The unprotected graphene samples (not
protected by PR) are then etched by plasma formed from the
ionization of Ar gas particles in a vacuum of 6 × 10−7 Torr
at 50 W RF power for 2.5 min before the samples are treated
with a chemical remover. Subsequently, the samples were placed
in a chemical remover in an ultrasonic bath for ∼1 h at 60◦C,
the ultrasonic bath was turned off and the samples were left in
the chemical remover for 15 h. The samples were then rinsed in
di-ionised water and left to dry in a vacuum chamber for an hour.
The second fabrication stage involves forming metallic Cr and
Au electrodes as the source, drain, and voltage electrodes. The
electrode formation follows the same process as the graphene
channel formation, but the samples are post-baked in an oven
at 120◦C for 15 min instead of exposing to DUV on a hotplate.
Next, Cr is thermally evaporated using an Edwards Thermal
Evaporator. The Cr target was heated to ∼2000◦C for 8 s in
a vacuum pressure of 10−6 Torr to form a 5 nm layer of
Cr on the graphene samples. Thermal evaporation is a gentle
way of depositing Cr on the samples without destroying the
graphene channels already formed, and the Cr layer functions as
an adhesive layer between graphene and the Au metallic contacts
(Haslam et al., 2018). Using the Nordiko sputtering machine,
30 nm of Au was sputtered directly onto the Cr layer. The
treatment with chemical remover was repeated and the samples
were dried in a vacuum chamber for a further 1 hour.
The fabricated 1 cm × 1 cm chips consists of 15 GFET
devices, 5 asymmetric GFETs with the graphene channel length of
720 µm and 10 symmetric GFETs with graphene channel length
of 400 µm with both being 80 µm (Haslam et al., 2018). Overall,
the GFET sensors take approximately 3 days to fabricate and
a further 1–2 days for biofunctionalisation and characterisation
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FIGURE 1 | Overview of the processes for GFET fabrication (A) layer of graphene on Si/SiO2 substrate, (B) LoR deposition, (C) PR deposition, (D) sample below the
photolithography mask aligner for UV exposure, (E) etching of graphene channels and chemical developing process, (F) final stage of metallic Cr and Au deposition.
FIGURE 2 | Graphene field effect transistor (GFET) device; (A) symmetric GFET device with graphene channel length of 400 µm (symmetry by 3 voltage leads above
and below the graphene channel). Here Ch-1T refers to channel 1 top voltage leads, Ch-lB refers to channel 1 bottom voltage leads and Ch-2B refers to channel
2 bottom voltage leads; (B) GFET device with antibody bound Clusterin (at 1 pg/mL concentration), inset shows closer view of graphene channel and yellow dotted
lines indicate the drop of solutions on the two series GFET channels (diameter of the drop region is ∼900 µm).
of the sensors. Figure 2 shows two symmetric GFET sensors in
series in a device (deployed in this study) and when they are
exposed to Clusterin at a concentration of 1 pg/mL.
Functionalisation of GFETs
The GFETs were functionalised by immobilising the graphene
surface with an anti-Clusterin antibody using a linker molecule,
after which BSA was deposited and the final step involved
conjugation of the Clusterin antigen in varying concentrations
following the same protocol as Haslam et al. (2018). The steps
involved in the biofunctionalisation processes are illustrated
in Figure 3.
The Pyr-NHS ester linker molecules are a cross-linking agent
that react with special functionalised groups such as amino
groups on proteins. The linker molecule (1-pyrenebutanoic
acid succinimidyl ester) used belongs to N-Hydroxysuccinimide
(NHS) group known as Pyr-NHS ester. It has an aromatic pyrenyl
group that strongly interacts with the surface of graphene via
non-covalent π–π interactions and the succinimidyl ester group
covalently reacts with the amino group (NH2) of the antibody
(Huang et al., 2011). The linker molecule was applied at a
concentration of 2 mM and was allowed to incubate at 4◦C for
4 h, after which it was rinsed thrice with PBS and allowed to
dry in ambient temperature. Once dry, Raman and electrical
characterisation were performed followed by the binding of
anti-Clusterin antibody. The antibody (Ab) was applied at a
concentration of 20 µg/mL and was allowed to incubate following
the same procedure as for the linker stage. BSA was then
deposited on the GFET to block sites between the Ab regions
preventing non-specific binding. BSA increases the tendency of
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FIGURE 3 | Steps for GFET functionalisation (A) bare graphene, (B) annealed graphene (showing evaporation of water molecules), (C) attachment of Pyr-NHS ester
molecules with graphene, (D) anti-Clusterin antibody attachment to linkers (red), (E) BSA blocking (purple), and (F) binding of Clusterin (tri-colour molecules) with the
anti-Clusterin antibody.
FIGURE 4 | Raman Spectra of three monolayer graphene field-effect transistor (GFET) sensors after fabrication.
the antibody to bind with the antigen of interest and it also
improves the sensitivity of the sensor by decreasing background
noise as the additional sites are blocked (Biocompare, 2012). BSA
was deposited at a concentration of 0.5% and allowed to incubate
following the same procedure as for the linker and Ab stages.
The final step involved depositing Clusterin antigen on the
samples at varying concentrations from 1 to 100 pg/mL, followed
by the samples being incubated for 1 h at 37◦C before they
were allowed to dry in ambient temperature and characterised
using Raman spectroscopy and electrical 4-probe measurements
(Awan et al., 2011).
RESULTS
Characterization of GFETs
The GFETs were characterised using Raman Spectroscopy to
analyse the quality of the graphene channels (Ferrari et al.,
2006) and also with a semiconductor device parameter analyser
to determine the electrical properties of the GFETs. Raman
Spectroscopy is one of the most accurate, effective and non-
destructive tool for the characterisation of graphene because of
its sensitivity to important features and properties of graphene
such as defect (Ferrari, 2007), doping (Casiraghi et al., 2007),
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FIGURE 5 | Characteristic transfer curve ID–VG measurements of three
graphene channels with corresponding output ID–VD curves (inset).
Back-gated measurements showing forward and reverse sweep (from –100 to
100 V) demonstrate the bare graphene channels are electrically almost
identical.
TABLE 1 | The forward and reverse Dirac point voltages (DPV) and the resistance
of the three channels. The Dirac point voltages reveal that the GFET is p-doped.
Back-gate sweep rate was ∼ 20 V/s.
Channel Forward sweep Reverse sweep Resistance
Channel-1B 17 V 35 V 4086 
Channel-1T 35 V 22 V 3789 
Channel-2B 42 V 51 V 3852 
strain (Huang et al., 2009), and temperature (Calizo et al., 2007).
The Raman spectrum of graphene is made up of three main
features with different physical origins; they are the 2D peak
previously known as G′ peak, the G peak and D peak. In
monolayer graphene, the 2D peak is observed at a Raman shift
of ∼2700 cm−1, the G peak at a Raman shift of ∼1580 cm−1
and the D peak at a Raman shift ∼1350 cm−1 (Graf et al.,
2007; Mafra et al., 2007). Figure 4 shows Raman spectra of three
devices after fabrication, the intensity ratio I(2D)/I(G) position
for Ch-1T = ∼ 1.10, Ch-1B = ∼ 1.04, and Ch-2B = ∼ 1.20
and full width half maximum (FWHM) of the 2D peak for Ch-
1T = 59.8 cm−1, Ch-1B = 66.9 cm−1, and Ch-2B = 54.9 cm−1,
which confirms the graphene channels are monolayer, and the D
peak confirms the presence of defects, which is generally caused
by the fabrication process.
The GFETs were electrically characterised using a Keysight
B1500A semiconductor device parameter analyser interfaced to
a Cascade probe station in ambient temperature and a four-
probe ID–VD and ID–VG measurements were taken to study the
electrical properties and performance of the sensors such as its
sheet resistance, contact resistance, Dirac curve and mobility.
ID–VD measurements were taken on each sensor with a voltage
sweep from −50 mV to +50 V and compliance of 100 µA. The
sensors showed a linear response in current from changes in
FIGURE 6 | Comparison of the bare and annealed ID–VG curves with their
corresponding ID–VD curves (inset).
FIGURE 7 | Absorbance spectra of Pyr-NHS ester linker molecules at
0.2 µg/mL concentration (red curve) and a repeat measurement (blue curve)
off-set by 0.05 for clarity, showing the characteristic triple peaks due to the
presence of pyrene moiety.
drain voltage, showing the channels are Ohmic as shown in the
inset of Figure 5. Back-gated measurements were also performed
to obtain the ID–VG curve with a forward and reverse voltage
sweep from −100 to +100 V, with a fixed drain voltage of 50 mV,
Figure 5 (main panel). Data analysis was performed using the
SCRAMBLE software which was developed in-house and graphs
were plotted in Originlab. The ID–VG curves show the Dirac
curve of the graphene channels, revealing that the three channels
are hole doped. From the curves, the carrier mobility of the three
channels is found to be around 500–600 cm2/Vs (Zhong et al.,
2015; Bøggild et al., 2017). Table 1 shows the Dirac point voltages
(forward and reverse) and resistances for all three channels.
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FIGURE 8 | Characteristic curves for Channel-1B (A) ID–VD output curves for bare to BSA, (B) ID–VG transfer curves for bare to BSA, (C) ID–VD curves for BSA to
human chorionic gonadotropin (hCG) (100 ng), and (D) ID–VG curves for BSA to hCG (100 ng) with off-set currents shown for clarity. Antigen concentrations are in
units of g/mL.
During the transfer of CVD graphene onto a substrate, a
polymer PMMA is used to support the graphene while the Cu
substrate is etched. The PMMA often leaves a layer of residue
on the graphene surface and the residue remains on the surface
even after fabrication. The standard process of removing PMMA
using acetone does not completely remove the residues because
of strong Van der Waals interaction with graphene (Cheng et al.,
2011). The presence of the residue and also water molecules
from the graphene surface degrade the transport properties of
graphene, causing a weak p-doping (Lin et al., 2012). We explored
the effect of annealing to remove these contaminants from the
surface of graphene, thermally annealing GFETs improve their
performance increasing carrier mobility of the graphene channels
(Cheng et al., 2011; Pirkle et al., 2011; Kumar et al., 2013). We
annealed the GFET at 215◦C for 30 min. Figure 4 shows results
for Channel-1B at bare stage and after annealing. Figure 6 shows
results for Channel-1B at bare stage and after annealing.
Functionalisation of GFETs
After annealing, the resistance of the device decreased by 31%
from ∼4086 to ∼2822 , and the carrier mobility increased by
∼ 43% from 460 to 660 cm2/Vs, improving the performance of
the sensor. The annealed GFETs were then exposed to Pyr-NHS
ester linker molecules using the drop-cast method, as shown in
Figure 2B where the diameter of the solution drop is typically
∼ 1 mm. The linker molecules were also characterised using
absorbance spectra, which could easily resolve a concentration
level of 0.2 µg/mL, as shown in Figure 7. The data show clear
triple peaks in absorbance due to the pyrene moiety that is central
to the Pyr-NHS ester linker molecules, also observed by,Baek
et al. (2011) after functionalising carbon nanotubes for electrical
detection of DNA hybridisation. The data in Figure 7 also show a
repeat measurement (off-set for clarity) of the absorbance spectra
over the 220–400 nm wavelength range, demonstrating excellent
repeatability of the measurements. The independent absorbance
spectra essentially served to increase our confidence in the linker
solutions we deployed for the GFET sensor experiments.
Detection of Analytes Using GFETs
Following the functionalisation of the GFETs, Figures 8–10
show data from Channel-1B, Channel-1T, and Channel-2B for
ID−VD and ID−VG characteristic curves. Figures 8A,B shows
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FIGURE 9 | Characteristic curves for Channel-1T (A) ID–VD output curves for bare to BSA, (B) ID–VG transfer curves for bare to BSA, (C) ID–VD curves for BSA to
hCG (100 ng/mL), and (D) ID–VG curves for BSA to hCG (100 ng/mL), with off-set currents shown for clarity. Antigen concentrations are in units of g/mL.
data for bare to BSA functionalisation stages, with ID–VD
showing linear Ohmic response and ID−VG showing shifts
in the Dirac point from bare to linker stages. However, it
is interesting to note the Dirac points are at approximately
100 V limit of our measurement system for antibody to
BSA stages. Although the ID−VG characteristic curves provide
quantitative indication of the influence of charged molecules on
the surface of graphene, albeit with a relatively high standard
deviation, at present a more robust quantitative response
of the GFET sensors can be determined from the 4-probe
electrical resistance (4-PER) measurements of the ID−VD curves.
In contrast, Figure 8C shows the standard ohmic response
for functionalisation stages from BSA to Clusterin (at 1 to
100 pg/mL concentration levels) and 100 ng/mL of human
chorionic gonadotropin (hCG), whereas Figure 8D shows the
Dirac point is approximately constant around 25 V. This is
in agreement with our previous observations (Haslam et al.,
2018) that the Dirac point shift is typically in the few-volt
region for similar concentrations of hCG and is significantly
influenced by hysteresis and charge traps in the SiO2 substrate.
Figures 9, 10 show almost identical response of the GFETs
from bare to Clusterin antigen and hCG antigen detection.
Table 2 shows the corresponding data from the GFET sensors
from bare to Clusterin and hCG antigen stages based on the
ID−VD results.
DISCUSSION
Figure 11 shows plot of resistance change (Mean ± SD) for each
channel at all stages of the functionalisation process. The data
show that there is an approximate 30% reduction in resistance,
from bare stage when the channels are annealed (inset in
Figure 11). A further 30% reduction in resistance is observed
when the linker molecules are bound to the graphene surface. In
contrast, there is almost a negligible change in resistance when
the antibodies and BSA interface with the linker functionalized
GFETs. However, when 1 pg/mL of Clusterin is conjugated with
the antibodies on the GFETs, we observe an ∼118% increase in
resistance. We estimate a LoD ∼300 fg/mL (4 fM) for Clusterin
detection, similar to the LoD demonstrated for hCG detection
by Haslam et al. (2018) using our DC 4-PER measurement
technique. The LoD was estimated using LoD ∼ 3.3 (σ/S), where
σ is the standard deviation at low concentration (in our case
at the BSA stage) and S is the sensitivity coefficient or slope
of the calibration curve (over the log-linear dynamic range)
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FIGURE 10 | Characteristic curves for Channel-2B (A) ID–VD output curve for bare to BSA, (B) ID–VG transfer curve for bare to BSA, (C) ID–VD curve for BSA to
hCG (100 ng/mL), and (D) ID–VG curve for BSA to hCG (100 ng/mL), with off-set currents shown for clarity. Antigen concentrations are in units of g/mL.
TABLE 2 | Measured resistance and resistance change (%) for bare to BSA stages of functionalisation for the three channels and the corresponding mean and standard
deviation values.
Channel Bare ( ) Annealed ( ) 1R (%) Linker ( ) 1R (%) Antibodies ( ) 1R (%) BSA ( ) 1R (%)
Channel-1B 4086 2822 −31 1509 −47 1566 +3.8 1660 +6
Channel-1T 3789 2422 −36 1660 −31 1936 +16 1775 −8
Channel-2B 3852 2323 −35 1868 −20 1862 −0.3 1862 −2.4
Mean ± SD 3909 ± 128 2522 ± 216 −34 ± 2 1679 ± 147 −33 ± 11 1788 ± 160 6.5 ± 7 1766 ± 83 −1 ± 6
The percentage changes are calculated for the two nearest stages (i.e., bare to annealed, annealed to linker, etc.).
shown in Figure 11. The log-linear least squares solid line
fit to the data shown in Figure 11 is effectively a partial fit
of the Hill–Langmuir equation (Hill, 1910; Langmuir, 1918).
Figure 11 also shows a corresponding comparison with back-
gated measurements of Dirac voltage shifts normalized with
respect to the BSA stage. At 1 pg/mL of Clusterin concentration
the Dirac voltage shift of approximately 60 ± 22.9 V, from the
BSA stage, is clearly discernable (p < 0.001). At subsequent
concentrations of Clusterin, 10 and 100 pg/mL, a clear reduction
in the Dirac voltage shifts are observed. However, the standard
deviations of the measurements are relatively large, as also
observed by Tsang et al. (2019), and point to a future requirement
for further optimisation of our next generation of GFETs and
their fabrication processes. The initial 60 ± 22.9 V increase in
Dirac voltage shift at 1 pg/mL Clusterin concentration and the
subsequent gradual reduction in the Dirac voltage shift for 10
and 100 pg/mL indicate a reduction in the number of available
binding sites (anti-Clusterin antibodies) on the GFET sensors.
Thus, to the best of our knowledge, this is the first time such
a characteristic curve (Figure 11, graph on the right) for Dirac
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FIGURE 11 | Measured resistance (in ohms, Mean ± SD) for each functionalization stage with a log-linear least squares fit (solid line, effectively a partial
Hill–Langmuir equation fit) to the measured data from 1 to 100 pg/mL of Clusterin concentration and the fit parameters showing adjusted r2 ˜ 0.98 (left). The inset
shows corresponding percentage resistance change relative to the previous stage (with bare stage being 0% by definition). Note, the data in the inset for resistance
change at 1 pg/mL Clusterin is reduced by a factor of 4 for clarity and analyte concentrations are in units of g/mL. Corresponding back-gated measurements of Dirac
voltage shifts normalized with respect to the BSA stage, demonstrating a first-time observation of a characteristic response curve for the GFET biosensors (right).
voltage shift has been demonstrated for Clusterin detection using
CVD single layer GFETs that may also broadly be expected for
the detection of other molecular species. Table 3 shows a variety
of biosensing platforms and detection techniques in comparison
with our results reported in Table 4 using 4-PER and Dirac
voltage shift techniques.
We also tested the three GFET sensors for their specificity by
introducing a three-orders-of-magnitude higher concentration
(compared to 100 pg/mL of Clusterin) hCG antigen at a
concentration of 100 ng/mL; data are presented in Tables 2,
3 and a summary of the results are shown in Figure 11. The
three sensors resulted in only an average of −6 ± 3% change
TABLE 3 | Measured resistance and resistance change (%) for Clusterin (1 pg/mL) to hCG (100 ng/mL) stages of analyte detection for the three channels and the
corresponding mean and standard deviation values.
Channel Clusterin (1 pg) ( ) 1R (%) Clusterin (10 pg) ( ) 1R (%) Clusterin (100 pg) ( ) 1R (%) hCG (100 ng) ( ) 1R (%)
Channel-1B 3778 +127 4225 +11 5212 +23 4754 −9
Channel-1T 4084 +130 4697 +15 5406 +15 5244 −2
Channel-2B 3657 +101 3429 −6 4524 +32 4257 −6
Mean ± SD 3840 ± 180 117 ± 13 4117 ± 523 7 ± 9 5047 ± 378 23 ± 7 4752 ± 403 −6 ± 3
The Clusterin and hCG concentrations are in units of g/mL.
TABLE 4 | Other approaches deployed for biosensors in comparison with our GFET based four-probe electrical resistance (4-PER) detection technique.
Electrode materials Receptor system Detection technique LoD (pg/mL) References
SPCE-NPAu SPCE-NPAu/Streptavidin/Biotin-Aβ-42/anti-Aβ/anti-IgG-AP CV 100 Rama et al., 2014
Gold nanoparticles GNP/MUA/NHS-EDC/Aβ(1–42) monoclonal antibody
IgG/BSA/Aβ(1–42) peptide solution
EIS 1 Wu et al., 2014
SPCE/carbon SPCE/PANHS/anti-hCG Ab/BSA/hCG CV/electrochemical 1 Damiati et al., 2019
Au nanoparticles Au/PSA antibody/BSA/PSA/tPSA SPR 30 Uludag and Tothill, 2012
SPCE SPCE/Pyr-NHS/anti-CLU F(ab′)2/BSA/CLU CV/SWV 1 Islam et al., 2018
SPR chip-gold Gold film/EDC-NHS/anti-cTnT antibody/BSA/cTnT SPR 500 Pawula et al., 2016
Gold nanoparticles Gold electrode/AuNP/MPA self-assembly/EDC-NHS/BSA/HER2 EIS 500 Chun et al., 2013
Graphite electrodes Electrode/EDC-NHS/anti-CA125, anti-CA153, anti-CEA/BSA/CA125,
CA153, CEA/M-Pt-CA125Ab2, M-Pt-CA153 Ab2, M-Pt-CEA Ab2
DPV 7 Cui et al., 2014
PDMS/AuNP PDMS/AuNP/anti-human IgG(cTnI)/BSA/human IgG(cTnI) Colorimetric 10 Wu et al., 2010
GFET Graphene/Pyr-NHS/anti-CLU/BSA/CLU 4-PER 0.3 This work
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in resistance, demonstrating the excellent specificity of our
GFET sensors and the functionalisation protocols. These highly
promising results demonstrate the potential of our graphene
sensors as low-cost, repeatable, sensitive, and specific detection
platforms suitable for detecting a variety of other disease
diagnosis. Our future work involves the development of a novel
multiplexing platform exploiting the fact that these GFET sensors
are generic transducers of biological events.
CONCLUSION
We have reported the fabrication, functionalization, and
characterization of graphene FET sensors using Raman
spectroscopy, four-probe electrical measurements and
absorbance spectra using the highly collimated microbeam
of Diamond B23 beamline for the detection of a prominent
AD protein biomarker, Clusterin. The fabrication and
functionalisation protocols have enabled detection of Clusterin
from 1 to 100 pg/mL, with a limit-of-detection of ∼300 fg/mL
(4 fM) using 4-PER measurement technique. In contrast, a
characteristic curve for the Dirac voltage shift with Clusterin
concentration has also been demonstrated using back-gated
ID−VG measurements, although the standard deviation of
these results were relatively higher than the results from 4-
PER measurements. The GFET sensors were also found to
have a repeatable performance over an extensive range of
functionalisation stages from bare to 100 pg/mL of Clusterin
using 4-PER measurements. In addition, the sensors were found
to be highly specific, showing only a −6 ± 3% resistance change
compared to 100 pg/mL of Clusterin when a three-orders-of-
magnitude higher concentration of hCG was applied (100 ng/mL)
to the GFET sensors. Future work includes deploying the sensors
to detect a panel of biomarkers for the early detection of AD
(such as ApoE, Aβ, etc.) using a novel multiplexing platform
we are currently developing, which will be reported in a future
study. In addition, as the GFET sensors are generic transducers,
we anticipate their future applications in a variety of other disease
biomarker detection also, such as cancer and cardiovascular.
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